By Allison Sit Research from the University of Missouri found its Dermatology ECHO project improved accuracy of diagnosis. ECHO allows primary care providers and other clinicians to connect with dermatologists…
Read More
By Allison Sit The University of California San Francisco (UCSF) is apologizing for dermatologic experiments conducted on prisoners in the 1960s and 1970s. An internal investigation centered on research performed…
Read More
By Allison Sit The FDA is implementing changes to the iPLEDGE program that will alleviate administrative burdens for dermatologists. The changes come after two years of advocacy by the American…
Read More
By Allison Sit A study in the Journal of the National Medical Association found racial disparities that led to a delay in diagnosis and dermatologic care in patients with hidradenitis…
Read More
By Allison Sit An Arizona dermatologist is named an AAD Patient Care Hero after making a life-saving recommendation. Christopher Bengson, MD, MHS, FAAD, with the Indian Health Service in Phoenix…
Read More
By Allison Sit The City of Philadelphia issues a formal apology for unethical medical experiments performed at the Holmesburg Prison from the 1950s to the 1970s. The University of Pennsylvania…
Read More
By Allison Sit The founders of a Midwest-based dermatology group have made a donation to ensure future dermatologists receive training on business and healthcare advocacy. The gift will create The…
Read More
By Allison Sit The FDA recently issued warning letters to three companies for selling unapproved new drugs for mole and skin tag removal, according to a news release. Amazon.com, Ariella…
Read More
By Allison Sit Babies may have a lower risk of eczema if their mothers take vitamin D during pregnancy, according to a new study in the British Journal of Dermatology.…
Read More
By Allison Sit May marks the 20th anniversary of the Journal of Drugs in Dermatology. Launched in 2002 by dermatologist Perry Robins, MD, the JDD is now considered the fastest…
Read More
By Allison Sit The FDA has approved Olumiant (baricitinib) as a first-in-disease systemic treatment for adults with severe alopecia areata. Olumniant is a once-daily, oral JAK inhibitor. "People with alopecia…
Read More
By Allison Sit The Journal of Drugs in Dermatology is celebrating its 20th anniversary this month as the journal continues to make news. Healio covered several JDD studies in the…
Read More
